INTERIM ANALYSIS (IA) RESULTS from ASC2ESCALATE SUPPORT ASCIMINIB (ASC) AS A TREATMENT (TX) OPTION in CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) after 1 TYROSINE KINASE INHIBITOR (TKI)

Authors
Category Primary study
Conference30th Congress of theEuropean Hematology Association Annual Congress, EHA2025
Year 2025
This article has no abstract
Epistemonikos ID: 81605261e1521fc5240c69337a113b726c0ad1b4
First added on: Nov 15, 2025